NCT00002095
Completed
Not Applicable
A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus
DrugsGanciclovir
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 700
- Locations
- 19
Overview
Brief Summary
To evaluate the efficacy of oral ganciclovir in preventing progression to cytomegalovirus (CMV) disease (e.g., CMV retinitis, gastrointestinal CMV disease) in CMV-infected people with HIV infection and CD4 lymphocyte counts <= 100 cells/mm3. To evaluate the efficacy of this drug in reducing morbidity associated with coinfection by both CMV and HIV.
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 13 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Study Sites (19)
Loading locations...
Similar Trials
Completed
Not Applicable
A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus RetinitisCytomegalovirus RetinitisHIV InfectionsNCT00002134Roche Global Development450
Completed
Phase 2
The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIVCytomegalovirus RetinitisHIV InfectionsGastrointestinal DiseasesNCT00001034National Institute of Allergy and Infectious Diseases (NIAID)850
Completed
Not Applicable
A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDSColitisHIV InfectionsNCT00002273Hoffmann-La Roche
Completed
Not Applicable
An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous AccessCytomegalovirus RetinitisHIV InfectionsNCT00002135Hoffmann-La Roche
Terminated
Phase 3
Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and SepsisAcute Respiratory FailureNCT04706507Fred Hutchinson Cancer Center205